Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)

par Lindemann, Kristina, Malander, Susanne, Christensen, Rene D, Mirza, Mansoor R, Kristensen, Gunnar B, Aavall-Lundqvist, Elisabeth, Vergote, Ignace, Rosenberg, Per, Boman, Karin, Nordstrøm, Britta
Publié 2014

First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors

par Abdul Razak, Albiruni R., Mau-Soerensen, Morten, Gabrail, Nashat Y., Gerecitano, John F., Shields, Anthony F., Unger, Thaddeus J., Saint-Martin, Jean R., Carlson, Robert, Landesman, Yosef, McCauley, Dilara, Rashal, Tami, Lassen, Ulrik, Kim, Richard, Stayner, Lee-Anne, Mirza, Mansoor R., Kauffman, Michael, Shacham, Sharon, Mahipal, Amit
Publié dans J Clin Oncol (2016)

Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial

par del Campo, Josep M., Matulonis, Ursula A., Malander, Susanne, Provencher, Diane, Mahner, Sven, Follana, Philippe, Waters, Justin, Berek, Jonathan S., Woie, Kathrine, Oza, Amit M., Canzler, Ulrich, Gil-Martin, Marta, Lesoin, Anne, Monk, Bradley J., Lund, Bente, Gilbert, Lucy, Wenham, Robert M., Benigno, Benedict, Arora, Sujata, Hazard, Sebastien J., Mirza, Mansoor R.
Publié dans J Clin Oncol (2019)

Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA...

par Matulonis, Ursula A., Walder, Lydia, Nøttrup, Trine J., Bessette, Paul, Mahner, Sven, Gil-Martin, Marta, Kalbacher, Elsa, Ledermann, Jonathan A., Wenham, Robert M., Woie, Kathrine, Lau, Susie, Marmé, Frederik, Casado Herraez, Antonio, Hardy-Bessard, Anne-Claire, Banerjee, Susana, Lindahl, Gabriel, Benigno, Benedict, Buscema, Joseph, Travers, Karin, Guy, Holly, Mirza, Mansoor R.
Publié dans J Clin Oncol (2019)

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

par Oza, Amit M, Cook, Adrian D, Pfisterer, Jacobus, Embleton, Andrew, Ledermann, Jonathan A, Pujade-Lauraine, Eric, Kristensen, Gunnar, Carey, Mark S, Beale, Philip, Cervantes, Andrés, Park-Simon, Tjoung-Won, Rustin, Gordon, Joly, Florence, Mirza, Mansoor R, Plante, Marie, Quinn, Michael, Poveda, Andrés, Jayson, Gordon C, Stark, Dan, Swart, Ann Marie, Farrelly, Laura, Kaplan, Richard, Parmar, Mahesh K B, Perren, Timothy J
Publié dans Lancet Oncol (2015)

Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study

par Pulford, David J., Harter, Philipp, Floquet, Anne, Barrett, Catherine, Suh, Dong Hoon, Friedlander, Michael, Arranz, José Angel, Hasegawa, Kosei, Tada, Hiroomi, Vuylsteke, Peter, Mirza, Mansoor R., Donadello, Nicoletta, Scambia, Giovanni, Johnson, Toby, Cox, Charles, Chan, John K., Imhof, Martin, Herzog, Thomas J., Calvert, Paula, Wimberger, Pauline, Berton-Rigaud, Dominique, Lim, Myong Cheol, Elser, Gabriele, Xu, Chun-Fang, du Bois, Andreas
Publié dans BMC Med Ethics (2016)